New drug combination before surgery for stage 3 colon cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of drugs (QL1706 plus XELOX chemotherapy) given before surgery for stage 3 colon cancer that is MSS/pMMR. The goal is to see if this approach can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your colon cancer must be stage 3 and able to be removed with surgery.
- Your tumor must be 'MMR proficient' or 'MSS' (a lab test will confirm this).
- You should be in generally good health, able to care for yourself (ECOG score 0 or 1).
- You must not have had prior treatment with certain immunotherapy drugs (checkpoint inhibitors).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy medicine (QL1706) given before surgery to treat colon cancer that hasn't spread yet. It's designed for patients whose tumors have a specific gene feature (MSI-H/dMMR) and who haven't had any prior treatment for this cancer.
This study tests a new combination of drugs (QL1706 plus standard therapy) as a first treatment to shrink colon cancer that has spread only to the liver, with the goal of making the liver tumors removable by surgery. It is an early-phase trial to see how safe and effective this approach is.
This trial tests a new immunotherapy combination with chemotherapy given before breast cancer surgery, to shrink the tumor and improve outcomes. It's for people with early-stage triple-negative breast cancer whose tumors are larger than 2 cm.
This trial tests a combination of two medications, an immunotherapy (QL1706) and a blood-vessel-blocking drug (bevacizumab), for people with a type of colorectal cancer that has a specific genetic feature (MSI-H/dMMR). The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a new combination of drugs (QL1706 plus chemotherapy SOX) given before and after surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor before surgery and help prevent recurrence afterward.
This trial tests two new investigational drugs combined with either another experimental drug or an approved immunotherapy for advanced colorectal cancer that has stopped responding to standard chemotherapy. The goal is to see if these combinations can shrink tumors or slow cancer growth more effectively, and what side effects they may cause.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.